首页> 外文期刊>Systems and Synthetic Biology >Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine
【24h】

Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine

机译:表达抗原的免疫刺激脂质体作为可遗传编程的合成疫苗

获取原文
获取原文并翻译 | 示例
           

摘要

Liposomes are versatile (sub)micron-sized membrane vesicles that can be used for a variety of applications, including drug delivery and in vivo imaging but they also represent excellent models for artificial membranes or cells. Several studies have demonstrated that in vitro transcription and translation can take place inside liposomes to obtain compartmentalized production of functional proteins within the liposomes (Kita et al. in Chembiochem 9(15):2403-2410, 2008; Moritani et al.in FEBS J, 2010; Kuruma et al. in Methods Mol Biol 607:161-171, 2010; Murtas et al. in Biochem Biophys Res Commun 363(1): 12-17, 2007; Sunami et al. in Anal Biochem 357(1): 128-136, 2006; Ishikawa et al. in FEBS Lett 576(3):387-390, 2004; Oberholzer et al. in Biochem Biophys Res Commun 261(2):238-241,1999). Such a minimal artificial cell-based model is ideal for synthetic biology based applications. In this study, we propose the use of liposomes as artificial microbes for vaccination. These artificial microbes can be genetically programmed to produce specific antigens at will. To show proof-of-concept for this artificial cell-based platform, a bacterial in vitro transcription and translation system together with a gene construct encoding the model antigen beta-galactosidase were entrapped inside multilamellar liposomes. Vaccination studies in mice showed that such antigen-expressing immunostimulatory liposomes (AnExILs) elicited higher specific humoral immune responses against the produced antigen (beta-galactosidase)than control vaccines (i.e. AnExILs without genetic input, liposomal beta-galactosidase or pDNA encoding beta-galactosidase). In conclusion, AnExILs present a new platform for DNA-based vaccines which combines antigen production, adjuvanticity and delivery in one system and which offer several advantages over existing vaccine formulations.
机译:脂质体是通用的(亚)微米大小的膜囊泡,可用于多种应用,包括药物递送和体内成像,但它们也代表了人工膜或细胞的出色模型。数项研究表明,体外转录和翻译可以在脂质体内进行,以实现脂质体内功能蛋白的间隔化生产(Kita等人,Chembiochem 9(15):2403-2410,2008; Moritani等人,FEBS J ,2010; Kuruma等人,Methods Mol Biol 607:161-171,2010; Murtas等人,Biochem Biophys Res Commun 363(1):12-17,2007; Sunami等人,Anal Biochem 357(1)。 :128-136,2006; Ishikawa等人,FEBS Lett 576(3):387-390,2004; Oberholzer等人,Biochem Biophys Res Commun 261(2):238-241,1999)。这种最小的基于人工细胞的模型非常适合基于合成生物学的应用。在这项研究中,我们建议使用脂质体作为人工微生物进行疫苗接种。可以对这些人工微生物进行基因编程,以随意产生特定的抗原。为了显示该基于人工细胞的平台的概念证明,将细菌体外转录和翻译系统以及编码模型抗原β-半乳糖苷酶的基因构建体包裹在多层脂质体内。在小鼠中进行的疫苗接种研究表明,与对照疫苗(即无基因输入的AnExIL,脂质体β-半乳糖苷酶或编码β-半乳糖苷酶的pDNA)相比,这种表达抗原的免疫刺激脂质体(AnExILs)对产生的抗原(β-半乳糖苷酶)引起更高的特异性体液免疫反应。 )。总之,AnExILs为基于DNA的疫苗提供了一个新平台,该平台将抗原产生,佐剂化和递送整合在一个系统中,并且比现有疫苗制剂具有多个优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号